Skip to main content
. 2022 Nov 17;21:248. doi: 10.1186/s12933-022-01641-2

Table 2.

Estimated standardized mean difference between treatment groups before and after propensity score weighting

Variables Standardized differences Variance ratio
Raw Weighted Raw Weighted
TZD vs. SU
Age, year − 0.1263 − 0.0201 0.9809 1.0076
Male vs. Female 0.0043 − 0.0027 1.0016 0.9991
BMI, kg/m2 0.2837 − 0.0231 1.3183 0.9799
ln(FPG), mg/dL − 0.2419 0.0511 0.8574 1.2458
HT 0.0012 − 0.0129 0.9984 1.0205
eGFR group < 90 ml/min/1.73 m2 − 0.1037 − 0.0084 1.0659 1.0057
CVD − 0.1110 − 0.0004 0.6654 0.9989
Statin 0.1172 − 0.0205 0.8915 1.0186
HDL-C, mg/dL 0.0847 − 0.0100 1.0447 1.0442
Triglycerides, mg/dL − 0.0717 0.0803 1.0053 8.9630
LDL-C, mg/dL − 0.0729 − 0.0042 0.9187 1.0439
ACEi/ARB 0.0373 − 0.0142 1.0013 0.9991
DPP4i vs. SU
Age, year 0.2436 − 0.0111 1.0056 1.0908
Male vs. Female − 0.0374 0.0074 0.9870 1.0023
BMI, kg/m2 0.0280 0.0019 1.0991 1.0250
ln(FPG), mg/dL − 0.1617 0.0065 0.9541 1.1660
HT 0.1247 0.0027 0.8056 0.9957
eGFR group < 90 ml/min/1.73 m2 − 0.0207 0.0003 1.0149 0.9998
CVD 0.2104 − 0.0020 1.7271 0.9940
Statin 0.1275 − 0.0080 0.8810 1.0073
HDL-C, mg/dL − 0.0031 − 0.0053 1.1262 1.1293
Triglycerides, mg/dL − 0.0624 0.0109 0.7698 1.1319
LDL-C, mg/dL − 0.1704 0.0227 1.0567 1.2859
ACEi/ARB 0.0200 0.0015 1.0011 1.0001
SGLT2i vs. SU
Age, year − 0.1716 0.0036 1.1340 0.9964
Male vs. Female 0.0872 0.0154 1.0233 1.0048
BMI, kg/m2 0.5720 0.0204 1.6763 1.1053
ln(FPG), mg/dL − 0.4200 0.1604 0.6622 1.1047
HT 0.1278 0.0657 0.8029 0.8939
eGFR group < 90 ml/min/1.73 m2 − 0.3782 − 0.0722 1.1352 1.0444
CVD 0.5425 0.0225 2.8544 1.0672
Statin 0.1855 0.1306 0.8224 0.8670
HDL-C, mg/dL  − 0.1733 0.0041 0.9205 1.1982
Triglycerides, mg/dL − 0.0259 − 0.1194 1.0624 0.5776
LDL-C, mg/dL − 0.2757 − 0.0246 1.1049 1.3047
ACEi/ARB 0.0897 0.0026 1.0009 1.0001

ACEi: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; BMI: Body mass index; CVD: Cardiovascular disease; DPP4i: Dipeptidyl peptidase-4 inhibitors; eGFR: Estimated glomerular filtration rate; FPG: Fasting plasma glucose; HDL-C: High density lipoprotein cholesterol; HT: Hypertension; LDL-C: Low density lipoprotein cholesterol; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; SU: Sulfonylureas; TZD: Thiazolidinediones